Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy

Journal of Clinical Pharmacology

Volumn 44, Issue 11, 2004, Pages 1230-1234

  Levy, René H ^a   Ragueneau Majlessi, Isabelle ^a   Garnett, William R ^b   Schmerler, Michael ^c   Rosenfeld, William ^d   Shah, Jaymin ^e   Pan, Wei Jian ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Riverhills Healthcare Inc   (United States)

^d Comprehensive Epilepsy Care Center ^*  (United States)

^e GILEAD SCIENCES   (United States)

^f ELAN PHARMACEUTICALS   (United States)

Author keywords

Drug interactions; Epilepsy; Pharmacokinetics; Phenytoin; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 3A4; PHENYTOIN; ZONISAMIDE;

ADULT; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME ACTIVITY; EPILEPSY; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PHARYNGITIS; SEIZURE; STEADY STATE;

ADOLESCENT; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENYTOIN;

EID: 6344267015     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268045     Document Type: Article

References (16)

1. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24:91-103.
2. Browne T, Szabo G, Kres J. Drug interactions of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol. 1986;26:555.
3. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67-73.
4. Tasaki K, Minami T, Ieiri I, et al. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev. 1995;17:182-185.
5. Odani A, Hashimoto Y, Takayanagi K, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull. 1996;19:444-448.
6. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol. 2001;57:31-36.
7. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24:1401-1403.
8. Mather G, Carlson S, Trager W, Buchanan R, Levy R. Prediction of zonisamide interactions based on metabolic isozymes. Epilepsia. 1997;38(suppl 8):108.
9. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002;91:1923-1935.
10. Browne T, Leduc B. Phenytoin: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York: Raven; 2001.
11. Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit. 1986;8:293-296.
12. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994;17:323-326.
13. Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol Pharm Bull. 1996;19:1090-1092.
14. Ragueneau-Majlessi I, Bajpai M, Levy RH. Phenytoin: interactions with other drugs, in: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. New York: Raven, 2001.
15. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993;44:216-221.
16. Nakasa H, Nakamura H, Ono S, et al. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998;54:177-183.